Last updated on May 2019

A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma


Brief description of study

The purpose of this study is to assess the safety and tolerability profile of TB-403 (humanized monoclonal antibody against placental growth factor (PlGF)) in pediatric subjects with relapsed or refractory Medulloblastoma.

Detailed Study Description

The study will be conducted in 2 parts.

In part A, the maximum tolerated dose of TB-403 will be determined in pediatric subjects with relapsed or refractory Medulloblastoma (MB) and as well Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS).

In part B of the clinical trial, the safety and tolerability of TB-403 at the maximum tolerated dose will be evaluated in pediatric subjects with relapsed or refractory Medulloblastoma.

Clinical Study Identifier: NCT02748135

Find a site near you

Start Over

Study Director, Global Clinical Development

Saint Louis, MO United States
1.42miles
  Connect »